Determinants of Arterial Stiffness in Chronic Kidney Disease Stage 3

Natasha J. McIntyre¹, Richard J. Fluck¹, Christopher W. McIntyre¹,², Apostolos Fakis¹, Maarten W. Taal¹*¹*

¹ Department of Renal Medicine, Royal Derby Hospital, Derbyshire, United Kingdom, ² Department of Vascular Medicine, University of Nottingham, Nottingham, United Kingdom

Abstract

Background: Early chronic kidney disease (CKD) is associated with increased cardiovascular (CV) risk but underlying mechanisms remain uncertain. Arterial stiffness (AS) is associated with increased CV risk in advanced CKD, but it is unclear whether AS is relevant to CV disease (CVD) in early CKD.

Study Design: Cross-sectional.

Setting and participants: 1717 patients with previous estimated glomerular filtration rate (eGFR) 59–30 mL/min/1.73 m²; mean age 73±9y, were recruited from 32 general practices in primary care.

Outcomes: Increased arterial stiffness.

Measurements: Medical history was obtained and participants underwent clinical assessment, urine and serum biochemistry testing. Carotid to femoral pulse wave velocity (PWV) was determined as a measure of AS, using a Vicorder™ device.

Results: Univariate analysis revealed significant correlations between PWV and risk factors for CVD including age (r = 0.456; p<0.001), mean arterial pressure (MAP) (r = 0.228; p<0.001), body mass index (r = 0.124; p<0.001), waist to hip ratio (r = 0.214; p<0.001), eGFR (r = 0.074; p = 0.02), and high sensitivity C-reactive protein (r = 0.066; p = 0.006), HDL (r = 0.062; p = 0.01) and total cholesterol (r = 0.057; p = 0.02). PWV was higher in males (9.6 m/sec vs.10.3 m/sec; p<0.001), diabetics (9.8 m/sec vs. 10.3 m/sec; p<0.001), and those with previous CV events (CVE) (9.8 m/s vs. 10.3 m/sec; p<0.001). Multivariable analysis identified age, MAP and diabetes as strongest independent determinants of higher PWV (adjusted R² = 0.29). An interactive term indicated that PWV increased to a greater extent with age in males versus females. Albuminuria was a weaker determinant of PWV and eGFR did not enter the model.

Limitations: Data derived from one study visit, with absence of normal controls.

Conclusion: In this cohort, age and traditional CV risk factors were the strongest determinants of AS. Albuminuria was a relatively weak determinant of AS and eGFR was not an independent determinant. Long-term follow-up will investigate AS as an independent risk factor for CVE in this cohort.

Introduction

Multiple epidemiological studies attest that chronic kidney disease (CKD) is associated with increased cardiovascular risk compared to the general population, and may account for up to 50% of all deaths in this group [1]. In many studies people with early stage CKD are more likely to die from cardiovascular disease than progress to end stage kidney disease (ESKD) [2]. Hallan [3] reported that the risk of CKD progression is low until eGFR falls below 30 ml/min/1.73 m². In contrast even modest reductions in eGFR are incrementally associated with reduced survival [4]. The increased cardiovascular (CV) risk associated with advanced stages of CKD cannot be explained by traditional risk factors alone, but is attributable to a combination of traditional and non-traditional factors [5,6]. Arterial stiffness (AS) has been identified as one non-traditional risk factor associated with the large cardiovascular risk burden in CKD [7,8]. Arterial stiffness in CKD is proposed to
Aortic pulse wave velocity (aPWV) is a measure of AS and has predicted cardiovascular morbidity and mortality in a number of populations including the healthy elderly and people with hypertension, diabetes or ESKD on haemodialysis [10,11,12,13,14]. On the other hand, data regarding the relationship between AS and CKD in earlier stages appear conflicting. Several studies have reported an increase in arterial stiffness and CV risk associated with early CKD [15,16,17] but others have not [18,19,20]. More data are therefore required regarding the relationship between AS and markers of kidney disease in early stage CKD. The aim of our study was to investigate if previously identified determinants of AS are also relevant in a population of predominantly elderly people with CKD stage 3, representing the majority affected by CKD.

**Study Population and Methods**

Participants and Recruitment

We studied 1741 patients with CKD stage 3 recruited from general practitioner (GP) practices. The methods have previously been described in detail and are summarised here with emphasis on the measurement of aPWV [21,22]. Participants were recruited as part of the Renal Risk in Derby (RRID) study, a prospective cohort study planned to continue for 10 years, with the aim of studying renal and CV risk factors in patients with CKD stage 3 in a primary care setting. Eligible participants were 18 years or over, met the KDOQI criteria for CKD stage 3 (eGFR of 30–59 mL/min/1.73 m² on 2 or more occasions at least 3 months apart), were able to give informed consent and attend their GP practice for assessments. People who had previously received a solid organ transplant or who were terminally ill (expected survival <1 year) were excluded. The RRID study is being conducted by a single Nephrology Department, but participants were recruited directly from 32 GP practices in Derbyshire, UK. Study visits were conducted at participating GP practices by the researchers. Twenty-four participants were unable to have their aPWV readings. The intra-observer coefficient of variation for PWV comparing carotid and femoral pressure tracings after a stable pattern is obtained. The mild discomfort caused by the inflation of a cuff placed around the neck precluded us from doing multiple readings that were within 10% of each other were obtained. BP was calculated as the mean of these three readings. Hypertension was defined as a systolic BP ≥140 mmHg, diastolic BP ≥90 mmHg, or current antihypertensive medication [26]. Mean arterial pressure (MAP) was calculated as 1/3 the average SBP plus 2/3 the average DBP.

**Pulse wave velocity.** Carotid to femoral pulse wave velocity was measured as a marker of arterial stiffness, a critical determinant of cardiovascular outcomes in CKD [7,27,28], and considered the gold standard measurement of AS [12]. Measurements were performed using a Vicorder™ device (Skidmore Medical Ltd, Bristol, UK). The Vicorder™ is small, portable, non-invasive and non-operator dependant making it well suited for use in community based studies. Readings take only 2–3 minutes to complete. Assessments were performed after at least 5 minutes of rest, according to manufacturers’ instructions in the semi-prone position (at approximately 30°) to prevent venous contamination of the arterial signal. The participant had a neck-pad placed around their neck with the pressure pad over the right carotid area. A blood pressure cuff was placed around the patients’ upper right thigh. The distance between the supra-sternal notch and the thigh cuff was measured using the direct method. To eliminate the potential effect of abdominal obesity on the distance measurement, an imaginary line was drawn from the supra-sternal notch to the right shoulder and the measurement to the thigh cuff was made along the side of the body. The neck-pad and thigh cuff were inflated by the Vicorder to 60 mmHg and then deflated to obtain a pressure tracing. Aortic PWV is calculated by the Vicorder by comparing carotid and femoral pressure tracings after a stable pattern is obtained. The mild discomfort caused by the inflation of a cuff placed around the neck precluded us from doing multiple readings. The intra-observer coefficient of variation for PWV measurements was 6.3%.

**Skin Autofluorescence**

Skin autofluorescence (AF), a measure of skin Advanced Glycation Endproduct (AGE) deposition that has been identified as a marker of cumulative metabolic stress [29,30,31], was assessed on the left forearm using an AGE Reader™ device (DiagnOptics, Groningen, Netherlands). Three readings were taken and the average calculated. It was not possible to conduct these readings on dark skin. Values are expressed in arbitrary units [22].

**Albuminuria.** Albuminuria was assessed by measuring the urine albumin to creatinine ratio (ACR) on three consecutive early morning urine specimens collected prior to the clinic visit and stored in a refrigerator. Microalbuminuria was defined as a mean urine ACR of ≥2.5 mg/mmol in males or >3.5 mg/mmol in females and overt albuminuria as ≥30 mg/mmol [23].

**Estimation of glomerular filtration rate** (eGFR). Biochemical assessments were performed by autoanalyzer in a single laboratory. The creatinine assay has been standardised against an isotope dilution mass spectrometry (IDMS) method and the 4-variable MDRD equation modified for use with IDMS standardised creatinine measurement was used to estimate GFR. This study was commenced prior to publication of the
The study was approved by the Nottingham Research Ethics Committee 1 and abided by the principles of the Declaration of Helsinki. All participants provided written informed consent. The study was included on the National Institute for Health Research (NIHR) Clinical Research Portfolio (NIHR Study ID:6632) and was independently audited by QED Clinical Services in November 2009.

Statistical Analysis

Results presented are a cross sectional analysis of data from the first study visit. Continuous variables are reported as the mean and standard deviation (SD) if normally distributed or the median and inter-quartile range (IQR) if not. A t-test was used to compare two groups where variables were normally distributed and a Mann U Whitney test used if not. Pearson’s test was used to assess univariate correlations with aPWV for variables with normal distribution or Spearman’s test if distribution was not normal. Partial correlations were used to correct for MAP. Variables with skewed distribution (exponential) were log transformed for the correlations. SPSS version 15.0 was used for univariate analysis. P<0.05 was considered statistically significant.

Multivariable linear regression analysis, using the forward stepwise method, was used to identify independent determinants of arterial stiffness. P<0.05 was used for a variable to enter the model. The model was built using a hierarchical approach that introduced variables one-by-one on the basis of biological plausibility as well as strength of association in univariate analyses adjusted for age and diabetes. Nested models were tested using the Akaike Information Criterion (AIC). Models with a smaller AIC value were selected. An interactive term for age by gender was also tested in the final model. A scatter plot of regression residuals versus predicted values and Cook’s Distance plot were used for testing the assumptions of linear regression and identifying any outliers. The adjusted R-squared value is reported as a measure of goodness-of-fit. The regression coefficients (95% Confidence Interval) and standardised coefficients (Beta) from the final multivariable model are presented. STATA version 11.1 was used for multivariable analysis.

Results

Baseline characteristics are summarised in Table 1. Over a third of participants were obese (37%). Most (88%) had hypertension and 65% were treated with a renin angiotensin aldosterone system inhibitor (RAASI).

Mean aPWV was 9.9±2 m/sec. Aortic PWV was significantly higher in participants who were male, had diabetes, had had previous CVE, had albuminuria (microscopic or overt), were hypertensive, were not obese (as defined by BMI), had a blood pressure over 130/80 mmHg or were ≥75 years of age (Table 2). People who evidenced increased central fat distribution (central obesity), anaemia, were receiving antihypertensive medication, had CKD stage 3B or who had previously smoked also had significantly higher aPWV (Table 2). Age evidenced the strongest correlation with aPWV before and after adjusting for MAP (Table 3). Mean arterial pressure was also strongly correlated with aPWV. Other significant correlations are shown in Table 3. Adjustment for MAP produced little change in the correlations. Multivariable analysis was performed to identify independent determinants of a higher aPWV (Table 4; adjusted R² = 0.29). The strongest and most significant of these were age, MAP, diabetes and BMI. Interestingly, BMI showed a negative relationship with aPWV. Other relatively weak independent determinants included serum total protein, log urine ACR and HDL cholesterol. An interactive term indicated that PWV increased to a greater extent with age in males versus females.

Discussion

We have identified age as the strongest determinant of arterial stiffness in this cohort of predominantly elderly patients with CKD stage 3. Other significant independent determinants of aPWV included traditional cardiovascular risk factors such as blood pressure, diabetes, obesity and a marker of dyslipidaemia. Markers of CKD were associated with aPWV only in univariate analysis (eGFR) or were weak determinants of aPWV (albuminuria). Our

Table 1. Baseline characteristics.

|                | Females n | Males n | Total n |
|----------------|-----------|---------|---------|
| Age (years)    | 73 (66–79)| 1037 75 | 680 74 (67–79) |
| Ethnicity white| 1014 (98)| 1037 661 (97) | 680 1675 (98) |
| Diabetes       | 158 (15)| 1037 129 (19)* | 680 287 (17) |
| Previous CVE   | 185 (18)| 1037 195 (29)* | 680 380 (22) |
| Current smoker | 47 (5) | 1037 31 (5) | 680 78 (4.5) |
| Previous smoker| 407 (39)| 1037 444 (65)* | 680 851 (50) |
| BMI (kg/m²)    | 3.0 (2.56–3.25) | 1037 27.8 (25.7–30.5)* | 680 28.4 (25.6–31.8) |
| Systolic BP (mmHg) | 133±9 | 1037 136±18* | 680 134±18 |
| Diastolic BP (mmHg) | 72±11 | 1037 74±11* | 680 73±11 |
| MAP (mmHg)     | 92±12 | 1037 94±11* | 680 93±12 |
| eGFR (mL/min/ 1.73 m²) | 54.7 (46.7–71.1) | 1037 51.1 (44.1–57.6)* | 680 53.3 (45.5–59.8) |
| HDL Cholesterol (mmol/L) | 1.55 (1.27–1.85) | 1032 1.19 (1.00–1.45) | 676 1.40 (1.13–1.71) |
| Total cholesterol (mmol/L) | 4.90 (4.10–5.80) | 1032 4.20 (3.60–4.98)* | 676 4.6 (3.9–5.5) |
| Serum total protein (g/L) | 74.2±4.8 | 1031 74.4±4.9 | 677 74.3±4.9 |
| Serum albumin (g/L) | 40.5±3.0 | 1036 40.9±3.3* | 678 40.7±3.2 |
| Corrected calcium (mmol/L) | 2.39±0.10 | 1033 2.35±0.09* | 673 2.38±0.10 |
| Phosphate (mmol/L) | 11.15±0.17 | 1018 1.05±0.18* | 667 1.11±0.18 |
| UACR (mg/g) | 0.23 (0.00–0.90) | 1035 0.63 (0.00–3.27)* | 679 0.33 (0.00–1.50) |
| CKD 3B 208 (20) | 1037 194 (29)* | 680 402 (23) |
| aPWV (m/sec) | 9.7±2 | 1037 10.3±2* | 680 9.9±2 |
| hs CRP (mg/L) | 2.23 (1.13–4.67) | 1036 2.21 (1.14–4.28) | 680 2.22 (1.13–4.50) |
| Waist to Hip Ratio | 0.86 (0.81–0.90) | 1037 0.98 (0.94–1.02)* | 680 0.91 (0.84–0.97) |
| SAF (AU) | 2.60 (2.30–3.00) | 1023 2.73 (2.33–3.18)* | 665 2.67 (2.30–3.07) |

Data are mean±SD, median (IQR) or number (%). *P<0.05 versus females.

aPWV = aortic pulse wave velocity; AU = Arbitrary units.; BP = blood pressure; BMI = body mass index; CKD 3B = eGFR 30–44 mL/min/1.73 m²; CVE = cardiovascular event; eGFR = estimated glomerular filtration rate; HDL = high density lipo-protein; hs CRP = high sensitivity C-reactive protein; MAP = mean arterial pressure; SAF = skin autofluorescence; UACR = urine albumin to creatinine ratio. doi:10.1371/journal.pone.0055444.t001
data therefore suggest that markers of kidney disease are not strong determinants of AS in early CKD and that traditional risk factors for CVD may be more important, or that mechanisms unrelated to AS mediate the association between early CKD and increased cardiovascular risk in this population.

Published data regarding the relationship between AS and CKD appear contradictory. Studies of patients receiving dialysis or with advanced CKD reported significantly increased AS compared with the general population [32,33] but results from studies that included those with earlier stages of CKD are variable. A number of studies have reported associations with reduced GFR and increased AS [15,17,34]. In a relatively small study of 102 people with a wide spectrum of CKD (stages 1–5) a clear stepwise increase corresponding to stage of CKD was reported [15]. Multivariable analysis confirmed an independent association between GFR and aPWV; however only a small number of studies that included those with earlier stages of CKD are variable.

Table 2. aPWV readings in selected subgroups.

|                          | Yes       | No        | P value  |
|--------------------------|-----------|-----------|----------|
| Male                     | 10.3 ± 2.0| 9.7 ± 2.0 | < 0.001  |
| Diabetes                 | 10.3 ± 2.0| 9.8 ± 2.0 | < 0.001  |
| Previous CVE             | 10.3 ± 0.7| 9.8 ± 0.6 | < 0.001  |
| Albuminuria*             | 10.3 ± 2.0| 9.8 ± 2.0 | < 0.001  |
| Hypertension†            | 10.0 ± 2.0| 9.1 ± 2.0 | < 0.001  |
| BP < 130/80 at baseline  | 9.2 ± 1.7 | 10.3 ± 2.1| < 0.001  |
| Obese                    | 9.5 ± 1.9 | 10.1 ± 2.0| < 0.001  |
| Age < 75 years           | 9.1 (8.1–10.3) | 10.5 (9.4–11.8)| < 0.001  |
| Anaemia                  | 10.2 ± 1.9| 9.8 ± 2.0 | 0.003    |
| Central Obesity          | 9.9 ± 2.2 | 9.5 ± 1.9 | 0.007    |
| On antihypertensive med. | 10.0 ± 2.0| 9.6 ± 2.1 | 0.007    |
| CKD stage 3B             | 10.1 ± 2.2| 9.8 ± 2.1 | 0.009    |
| Previous Smoker          | 10.0 ± 2.1| 9.8 ± 1.9 | 0.011    |

Data are presented as mean ± standard deviation or median (interquartile range).
aPWV (aortic pulse wave velocity) readings expressed as m/sec.

Table 3. Significant Correlations with aPWV.

|                          | Total Cohort (unadjusted) | Total Cohort (adjusted for MAP) |
|--------------------------|---------------------------|--------------------------------|
|                          | r            | P value |              | r            | P value |
| Age (years)              | 0.456*        | < 0.001 |              | 0.461        | < 0.001 |
| MAP (mmHg)               | 0.228         | < 0.001 |              | –            | –       |
| Urine ACR (mg/mmol)†     | 0.124         | < 0.001 | 0.111        | < 0.001      |
| Waist to Hip ratio†      | 0.124         | < 0.001 | 0.121        | < 0.001      |
| BMI (kg/m²)†             | –0.122        | < 0.001 | –0.133       | < 0.001      |
| Skin autofluorescence†    | 0.117         | < 0.001 | 0.133        | < 0.001      |
| Total Protein (g/L)      | 0.084         | 0.001   | 0.049        | 0.046        |
| eGFR (mL/min/1.73 m²)    | –0.074*       | < 0.002 | –0.096       | < 0.001      |
| hs CRP‡                  | 0.066         | 0.006   | 0.057        | 0.020        |
| HDL Cholesterol (mmol/L) | –0.062        | 0.010   | –0.069       | 0.005        |
| Total Cholesterol (mmol/L) | –0.057      | 0.018   | –0.100       | < 0.001      |

* Spearman correlation, otherwise Pearson correlation used. For adjusted values partial correlations were used.† = log transformed data. r = correlation coefficient.

Table 4. Independent Determinants of higher aPWV.

|                          | Total Cohort Adjusted R² = 0.29 |
|--------------------------|---------------------------------|
| B (95% CI)               | β (95% CI) | p value |
| Age (10 years)           | 1.09 (0.94 to 1.24) | 0.49 | < 0.001 |
| Gender (female)          | 1.46 (0.07 to 2.85) | 0.35 | 0.04   |
| MAP (10 mmHg)            | 0.43 (0.35 to 0.50) | 0.24 | < 0.001 |
| Diabetes Mellitus        | 0.61 (0.38 to 0.83) | 0.11 | < 0.001 |
| Body Mass Index (kg/m²)  | –0.042 (–0.058 to –0.025) | –0.11 | < 0.001 |
| Total serum protein      | 0.025 (0.0084 to 0.042) | 0.06 | 0.003  |
| [UACR (mg/mmol)          | 0.060 (0.0061 to 0.11) | 0.05 | 0.03   |
| HDL Cholesterol (mmol/L) | –0.21 (–0.42 to –0.028) | –0.046 | 0.047 |
| Interactive term age by  | –0.22 (–0.41 to –0.031) | –0.39 | 0.02   |

B = un-standardised coefficient (95% confidence intervals). β = standardized coefficient (Beta). F = female.

Table 4. Independent Determinants of higher aPWV.

|                          | Total Cohort Adjusted R² = 0.29 |
|--------------------------|---------------------------------|
| B (95% CI)               | β (95% CI) | p value |
| Age (10 years)           | 1.09 (0.94 to 1.24) | 0.49 | < 0.001 |
| Gender (female)          | 1.46 (0.07 to 2.85) | 0.35 | 0.04   |
| MAP (10 mmHg)            | 0.43 (0.35 to 0.50) | 0.24 | < 0.001 |
| Diabetes Mellitus        | 0.61 (0.38 to 0.83) | 0.11 | < 0.001 |
| Body Mass Index (kg/m²)  | –0.042 (–0.058 to –0.025) | –0.11 | < 0.001 |
| Total serum protein      | 0.025 (0.0084 to 0.042) | 0.06 | 0.003  |
| [UACR (mg/mmol)          | 0.060 (0.0061 to 0.11) | 0.05 | 0.03   |
| HDL Cholesterol (mmol/L) | –0.21 (–0.42 to –0.028) | –0.046 | 0.047 |
| Interactive term age by  | –0.22 (–0.41 to –0.031) | –0.39 | 0.02   |

B = un-standardised coefficient (95% confidence intervals). β = standardized coefficient (Beta). F = female.

Table 4. Independent Determinants of higher aPWV.

|                          | Total Cohort Adjusted R² = 0.29 |
|--------------------------|---------------------------------|
| B (95% CI)               | β (95% CI) | p value |
| Age (10 years)           | 1.09 (0.94 to 1.24) | 0.49 | < 0.001 |
| Gender (female)          | 1.46 (0.07 to 2.85) | 0.35 | 0.04   |
| MAP (10 mmHg)            | 0.43 (0.35 to 0.50) | 0.24 | < 0.001 |
| Diabetes Mellitus        | 0.61 (0.38 to 0.83) | 0.11 | < 0.001 |
| Body Mass Index (kg/m²)  | –0.042 (–0.058 to –0.025) | –0.11 | < 0.001 |
| Total serum protein      | 0.025 (0.0084 to 0.042) | 0.06 | 0.003  |
| [UACR (mg/mmol)          | 0.060 (0.0061 to 0.11) | 0.05 | 0.03   |
| HDL Cholesterol (mmol/L) | –0.21 (–0.42 to –0.028) | –0.046 | 0.047 |
| Interactive term age by  | –0.22 (–0.41 to –0.031) | –0.39 | 0.02   |

B = un-standardised coefficient (95% confidence intervals). β = standardized coefficient (Beta). F = female.

Table 4. Independent Determinants of higher aPWV.
with increasing number of components of the metabolic syndrome irrespective of GFR [36]. In one analysis of data from the Framingham Heart Study that included 181 patients with early CKD and characteristics very similar to ours (mean age 70 years, mean eGFR 31 mL/min/1.73 m², median urinary ACR 10 mg/g), AS was not different between those with or without CKD (defined by reduced GFR) after multivariable adjustment at baseline. In a longitudinal analysis, increased AS was not associated with increased risk of developing CKD [6]. On the other hand, higher aPWV was associated with elevated urinary albumin excretion at baseline and increased risk of developing microalbuminuria. Finally, in the Nephro Test cohort of 180 patients with CKD (mean age 59.6 years, eGFR 32 mL/min/1.73 m²) aortic PWV remained stable during 3.5 years of follow up despite a significant decline in GFR and an increase in albuminuria. Interestingly, increased carotid circumferential wall stress and pulse pressure were associated with a greater risk of progression to ESKD [19]. Taken together, published data show that arterial stiffness increases in advanced stages of CKD but that changes are more variable in early stages, probably reflecting differences in the populations studied, particularly with respect to age. Thus the lack of an independent negative association between eGFR and increased aPWV in our study as well as the weak association between urinary ACR and increased aPWV are probably attributable to the fact that our study population was predominantly elderly, the range of eGFR values was relatively small and albuminuria was present only in a small minority. These observations are nevertheless important because our study cohort is representative of the majority of people affected by early stage CKD, at least in the UK.

Previous studies have also identified age, blood pressure and the presence of diabetes as determinants of higher aPWV [6,17,20]. Our observation that aPWV increased to a greater extent with age in males versus females is consistent with data from another study that identified male gender as an independent determinant of increased aPWV in a large cohort of people with CKD [17]. The increase in AS with age is proposed to be due to overproduction of abnormal collagen fibres and a loss of elastin from the extracellular matrix [9,37]. It is not clear, however, whether this is a time dependent phenomenon directly related to chronological age or if it reflects exposure to other risk factors. Hypertension has long been recognised as a major determinant of arterial stiffness due to the associated medial hypertrophy [38]. The association between diabetes and arterial stiffness may be due to accumulation of advanced glycation endproducts (AGE) that provoke structural changes in the arterial wall [22] and the generation of reactive oxygen species that deactivate nitric oxide resulting in endothelial dysfunction [39].

BMI had an inverse relationship with aPWV. This is surprising because AS has previously been associated with obesity, particularly abdominal obesity [40], and increased waist to hip ratio was associated with higher aPWV in our univariate analysis. We have previously described that BMI decreased with age in our cohort, likely reflecting a loss of muscle mass [21]. Our observation may therefore be explained by lower BMI acting as marker of increased age (the dominant determinant of aPWV) that could not be completely corrected for in the multi-variable analysis. Furthermore, we have previously shown that measures of obesity that include central fat distribution are more closely related to important risk factors in those with CKD than BMI [41].

There are several limitations to this study. First, this analysis includes only cross-sectional data and we are therefore unable to draw any firm conclusions regarding possible causal relationships between AS and the determinants identified. However, the planned 10-year follow up of the cohort will allow us to investigate the factors that contribute to AS prospectively. Many studies have used aplanattonometry devices (SphygmoCor™ or Complior™) to measure PWV [17,19,20], but these are operator dependent, time consuming to use and not easy to transport. We therefore used the more portable Vicorder™ device which is also operator independent and requires only minutes to obtain a reading. Vicorder™ measurements of aPWV have been shown to be reproducible and correlate well with SphygmoCor™ measurements [42] but as yet there is no agreed method for making direct comparisons between results obtained by different methods [43]. A third limitation of our study is the absence of normal controls. Finally, participants comprised only 22% of people invited to participate and may therefore not be representative of all people with CKD stage 3. We were unable for ethical reasons to obtain data on non-participants but our study population was similar to a large population of people with CKD stage 3 derived by pooling data on all patients from several GP databases, suggesting that our participants were broadly representative of patients with CKD stage 3 in primary care in the UK, though with a low proportion of people from ethnic minorities [44]. Strengths of the study include the large cohort size, robust measures of eGFR and UACR, and detailed clinical assessment of each participant. A single operator performed all assessments, eliminating inter-observer variability.

Conclusion

Age was the strongest determinant of arterial stiffness in this cohort of predominantly elderly patients with CKD stage 3. Other significant independent determinants of aPWV included traditional cardiovascular risk factors such as blood pressure, diabetes, obesity and a marker of dyslipidaemia. Markers of CKD were associated with aPWV only in univariate analysis (eGFR) or were weak determinants of aPWV (albuminuria). Long term follow-up will investigate the importance of arterial stiffness as an independent risk factor for cardiovascular events in this cohort.

Acknowledgments

Thanks go to the collaborating GP practices and their staff. In addition we gratefully acknowledge the invaluable assistance of Mrs Diane Taal, Ms Rani Uppal, Mrs Rebecca Packington, Mrs Maureen Franklin, Mrs Sue Hodkinson, Mr Richard Turck and Mrs Paula Welch. We also thank all the participants for their time and commitment.

The results presented in this paper have not been published previously in whole or in part, except in abstract form.

Author Contributions

Conceived and designed the experiments: NJM RJF CWM AF MWT. Performed the experiments: NJM MWT. Analyzed the data: NJM AF MWT. Wrote the paper: NJM RJF CWM AF MWT.

References

1. Vanholder R, Massy Z, Argiles A, Spasovsky G, Verbeke F, et al. (2005) Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20: 1048–1056.

2. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH (2004) Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164: 659–663.
Determinants of Arterial Stiffness in CKD Stage 3

3. Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, et al. (2006) Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ 333: 1047.

4. Go AS, Chertow GM, Fan D, McCalloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med 351: 1296-1305.

5. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, et al. (2008) Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3: 305–321.

6. Upadhyay A, Hwang SJ, Mitchell GF, Vasan RS, Vita JA, et al. (2009) Arterial stiffness in mild-to-moderate CKD. J Am Soc Nephrol 20: 2044–2053.

7. Safar ME, London GM, Plante GE (2004) Arterial stiffness and kidney function. Hypertension 43: 163–168.

8. Mitchell GF (2004) Increased aortic stiffness: an unfavorable cardiorespiratory connection. Hypertension 45: 151–153.

9. Chue CD, Townsend JN, Steeds RP, Ferro CJ (2010) Atrial stiffness in chronic kidney disease: causes and consequences. Heart 96: 817–823.

10. Sutton-Tyrrell K, Najjar SS, Boutadrea AU, Venkitachalam L, Kupelian V, et al. (2005) Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 111: 3340–3349.

11. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, et al. (2002) Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 106: 2085–2090.

12. Lauren S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, et al. (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27: 2508–2505.

13. Blacher J, London GM, Safar ME, Mourad JJ (1999) Influence of age and end-stage renal disease on the stiffness of carotid wall material in hypertension. J Hypertens 17: 237–244.

14. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, et al. (2001) Atrial wave reflections and survival in end-stage renal failure. Hypertension 38: 434–438.

15. Wang MC, Hsai WC, Chen JY, Huang JJ (2005) Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 45: 494–501.

16. Mourad J, Pannier B, Blacher J, Rudnichi A, Benetos A, et al. (2001) Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int 59: 1384–1391.

17. Townsend RR, Wimmer NJ, Chirinos JA, Parsa A, Weir M, et al. (2010) Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens 23: 282–289.

18. Briet M, Boeze E, Laurent S, Fassot C, London GM, et al. (2006) Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int 69: 590–597.

19. Briet M, Collin G, Karras A, Laurent S, Boeze E, et al. (2011) Arterial remodeling associated with CKD progression. J Am Soc Nephrol 22: 967–974.

20. Temmar M, Lieube S, Renard C, Garnichon S, Esper NE, et al. (2010) Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertension 28: 163–169.

21. McIntyre NJ, Fluck R, McIntyre CW, Taal MW (2011) Risk Profile in Chronic Kidney Disease Stage 3: Older versus Younger Patients. Nephron Clinical Practice 119: e209-e276.

22. McIntyre NJ, Fluck R, McIntyre CW, Taal MW (2011) Skin Autofluorescence and the Association with Renal and Cardiovascular Risk Factors in Chronic Kidney Disease Stage 3. Clin J Am Soc Nephrol.

23. National Institute for Health and Clinical Excellence (2008) Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care. The National Institute for Health and Clinical Excellence. www.nice.org.uk/nicemedia/pdf/CG073NICEGuideline.pdf.

24. The World Health Organization and the International Diabetes Federation. (2006) The definition and diagnosis of diabetes mellitus and intermediate glycaemia. WHO Press.